INTERVENTIONS FOR IMPROVING OUTCOMES OF CHILDREN WHO ARE DEAF OR HARD OF HEARING
Professor Teresa Y C Ching
Professorial Fellow, NextSense Institute, Sydney;
Conjoint Professor, Macquarie University, Sydney;
Honorary Professor, University of Queensland, Brisbane, Australia
RESEARCHER PROFILE
Filmed in Sydney | June 2025
About two to six per thousand children have a hearing loss that prevents them from achieving their full potential in life. They experience many more difficulties in cognitive, language and social development than their hearing peers. We know that early detection through newborn hearing screening is crucial, but less is known about how intervention can best be targeted to meet the needs of individual children and their families.
Professor Teresa Ching has led population-based studies that drive evidence-based practice in intervention for improving outcomes of children who are deaf or hard of hearing. Much of her research findings have been translated into practice and policy. However, many children from culturally and linguistically diverse backgrounds remain vulnerable, requiring intervention tailored to their needs. Furthermore, many children have undetected, untreated hearing problems when they enter school, thereby reducing their educational attainment and social participation.
Teresa is a Conjoint Professor at NextSense Institute and Macquarie University, and an Honorary Professor at the University of Queensland in Australia. Her current research focuses on devising culturally sensitive practices in early detection and intervention to maximise children’s outcomes. Working with international colleagues, her current research is also directed towards developing global guidelines and recommendations for hearing screening beyond the newborn period, so that all children can benefit from early detection and intervention. The ultimate goal is to attain equity of care and outcomes for all children with hearing difficulties.
Source: Supplied
-
Applying nanotechnology to chronic pain management
Dr Felicity Han is a Research Fellow and Leader in Pain Relief Innovation, at the Australian Institute for Bioengineering and Nanotechnology in the University of Queensland. Dr Han’s research interests sit at the interface of drug delivery and the pain field. Her overarching research goal is to improve the quality of day to day life of patients suffering from chronic pain, by applying nanotechnology to the development of novel highly effective pain-killer products for improving chronic pain management.
-
Therapies for chronic myeloid leukaemia
Professor Tim Hughes is an international expert in the biology and treatment of leukaemia. He led the establishment of the molecular response criteria that are used world-wide to measure response in chronic myeloid leukaemia (CML) and has led many of the key Global and National trials. His group has successfully developed predictive bioassays and molecular targets that influence the way CML patients are managed world-wide. He has published over 350 papers that have been cited over 65,000 times.
-
Hormone receptor positive breast cancer and therapy resistance
Prof Elgene Lim is a medical oncologist at St Vincent’s Hospital and Head of the Connie Johnson Breast Cancer Research Lab at the Garvan Institute. Following his PhD at the Walter & Eliza Hall Institute where he identified the aberrant cells in carriers of the BRCA1 mutant gene, a hereditary breast cancer syndrome as the culprit cells giving rise to breast cancer, he furthered his research and clinical training at the Dana-Farber Cancer Institute and Harvard Medical School. He was awarded the National Breast Cancer Foundation Practitioner Fellowship in 2014 and returned from Boston to Australia. In 2017, he was awarded the inaugural National Breast Cancer Foundation Endowed Chair, and subsequently appointed the Principal Cancer Theme Lead at UNSW.
